ETNB•benzinga•
89bio Announces Completion Of Enrollment In Phase 3 ENTRUST Trial For Severe Hypertriglyceridemia; Topline Data Expected In H2 2025. Phase 3 ENLIGHTEN Program For MASH Continues Enrollment. Cash And Equivalents Total $440M As Of Dec 31, 2024
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga